Skip to content
Umoja Biopharma
  • Our Company
    • Leadership
    • Board of Directors
    • Advisory Board
    • Our Team
    • Investors
  • Our Science
    • Overview
    • Manufacturing
    • Partnerships
  • Our Pipeline
  • News + Resources
    • Press Releases
    • In The Media
    • Blog
    • White Papers
    • Presentations
  • Careers
  • Contact
  • Our Company
    • Our Team
  • Our Science
    • Overview
    • Manufacturing
    • Partnerships
  • Our Pipeline
  • News + Resources
    • Press Releases
    • In The Media
    • Blog
    • White Papers
    • Presentations
  • Careers
  • Contact
Umoja Biopharma
  • Our Company
    • Our Team
  • Our Science
    • Overview
    • Manufacturing
    • Partnerships
  • Our Pipeline
  • News + Resources
    • Press Releases
    • In The Media
    • Blog
    • White Papers
    • Presentations
  • Careers
  • Contact
  • Accessibility
  • Privacy Policy
  • Transparency in Coverage
  • Sitemap

Resource Category: White Paper

Lymphodepletion: systemic chemotherapy with acute toxicities and detrimental long-term consequences for anti-tumor immune function

Umoja’s RACR technology drives Synthetic Receptor Enabled Differentiation (ShRED) of iPSCs, a proprietary and uniquely scalable process for manufacturing potent and persistent engineered immune effector cells

 VivoVec: Our proprietary technology platform for in vivo gene delivery to T cells. 

The Next Step Forward in CAR T Development

CONTACT US
Umoja Biopharma
  • Our Company
  • Our Science
  • Manufacturing
  • Partnerships
  • Our Pipeline
  • Careers
  • Press Releases
  • In The Media
  • Blog
  • White Papers
  • Presentations

1616 Eastlake Ave E.
Suite 550
Seattle, WA 98102
info@umoja-biopharma.com

  • Accessibility
  • Privacy Policy
  • Transparency in Coverage
  • Sitemap

© 2023 Umoja Biopharma. All rights reserved.